나이관련황반변성에 의한 맥락막혈관신생에서 유리체내 베바시주맙 주입술의 장기효과

• 영문명: Long-term Effect of Intravitreal Bevacizumab for CNV Secondary to Age-Related Macular Degeneration
• 발행기관: 대한안과학회
• 저자명: 김용환 김응석 유승영 곽형우,Yong Hwan Kim, M.D., Eung Suk Kim, M.D., Seung Young Yu, M.D., Hyung Woo Kwak, M.D.
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume49,number12, 1935~1940쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2008.12.15

영문 초록

Purpose: To investigate the long-term therapeutic effect and safety of repeated intravitreal bevacizumab injections for managing choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: Clinical data of 14 eyes of 14 patients who were treated with repeated (3 times or more) intravitreal bevacizumab injections for secondary to AMD and followed up for 12 months were collected. Patients were treated with 1.25 mg of intravitreal bevacizumab. Bevacizumab was injected at 6-week intervals. Reinjection was performed with the same method according to the physician’s decision. Results: Mean visual acuity change increased by 4.0 lines from 1.13±0.47 to 0.73±0.44 (LogMAR). Mean central retinal thickness change decreased by 114.8 µm from 240.3±123.8 µm to 125.5±39.4 µm. Visual acuity improved statistically significantly at 12 weeks after first intravitreal bevacizumab injections and was maintained for 12 months. Central retinal thickness decreased statistically significantly at 6 weeks after the first intravitreal bevacizumab injection and was maintained for 12 months. During the 12 months of 4 intravitreal bevacizumab injections, mean visual acuity change increased by 4.0 lines at 12 months and 4.4 lines at 7 months. Conclusions: Intravitreal bevacizumab injection causes a significant decrease in central retinal thickness and improvement in visual acuity in eyes with CNV due to AMD for 12 months.

키워드

Age-related macular degeneration, Avastin, Bevacizumab, Choroidal neovascularization, Optical coherence tomography